13F

Investor

Prosight Management, LP

CIK 0001617201 · filed 2026-02-13 · SEC filing

Q1 2026Q4 2025

13F book

$483.9M

Positions

38

Largest name

9.0%

Procept Biorobotics Corp · PRCT

Est. mark

—

Need a prior quarter to estimate
HoldingsActivity
Show puts & calls
NameTickerSharesValueWeightEst. markChange
Procept Biorobotics CorpPRCT1.38M$43.4M9.0%—Held
Galapagos Nv—1.07M$35.1M7.3%—Held
Janux Therapeutics, Inc.JANX2.39M$33M6.8%—Held
Adc Therapeutics SaADCT8.48M$29.9M6.2%—Held
Kura Oncology, Inc.KURA2.53M$26.3M5.4%—Held
Meiragtx Hldgs Plc—3.21M$25.5M5.3%—Held
Nektar TherapeuticsNKTR554.6K$23.4M4.8%—Held
Veeva Sys Inc—90.1K$20.1M4.2%—Held
Icon PlcICLR110K$20M4.1%—Held
Boston Scientific CorpBSX210K$20M4.1%—Held
Concentra Group Holdings Par—891K$17.5M3.6%—Held
Phreesia, Inc.PHR977.2K$16.5M3.4%—Held
Amicus Therapeutics Inc—1.15M$16.4M3.4%—Held
Select Med Hldgs Corp—1.04M$15.4M3.2%—Held
Syndax Pharmaceuticals IncSNDX665K$14M2.9%—Held
Zymeworks Inc.ZYME530.4K$14M2.9%—Held
Roivant Sciences Ltd.ROIV627.2K$13.6M2.8%—Held
Crinetics Pharmaceuticals In—262.9K$12.2M2.5%—Held
Avantor, Inc.AVTR898.5K$10.3M2.1%—Held
Shattuck Labs, Inc.STTK2.38M$8.69M1.8%—Held
Labcorp Holdings Inc.LH34.5K$8.66M1.8%—Held
GeneDx Holdings Corp.WGS55K$7.15M1.5%—Held
Alnylam Pharmaceuticals, Inc.ALNY17.1K$6.8M1.4%—Held
Immunovant, Inc.IMVT243.4K$6.19M1.3%—Held
Corbus Pharmaceuticals Hldgs—683.9K$5.57M1.1%—Held
Tectonic Therapeutic, Inc.TECX235K$4.9M1.0%—Held
CareDx, Inc.CDNA250K$4.71M1.0%—Held
Terns Pharmaceuticals Inc—95K$3.84M0.8%—Held
Rocket Pharmaceuticals Inc—743.9K$2.61M0.5%—Held
Orthopediatrics CorpKIDS136.7K$2.43M0.5%—Held
OnKure Therapeutics, Inc.OKUR816.9K$2.37M0.5%—Held
BridgeBio Pharma, Inc.BBIO30K$2.29M0.5%—Held
Abivax Sa—17K$2.29M0.5%—Held
Adicet Bio, Inc.ACET250.2K$2.11M0.4%—Held
Tempus AI, Inc.TEM35K$2.07M0.4%—Held
TrueBlue, Inc.TBI442.6K$2.01M0.4%—Held
Pliant Therapeutics, Inc.PLRX1.56M$1.9M0.4%—Held
Rein Therapeutics, Inc.RNTX442.6K$513.4K0.1%—Held

Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.